• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.

作者信息

Headlam John, Ford Alexander C, Gracie David J

机构信息

Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom.

Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.

出版信息

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.

DOI:10.1016/j.cgh.2017.05.017
PMID:28529166
Abstract
摘要

相似文献

1
Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.接受英夫利昔单抗治疗的炎症性肠病患者中反应性与前瞻性治疗药物监测：自我实现的预言
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.
2
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.英夫利昔单抗的原发性和继发性无应答：机制与对策
Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11.
3
Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.炎症性肠病生物治疗的主动和被动治疗药物监测是互补的，而非相互排斥的。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598. doi: 10.1016/j.cgh.2017.11.033.
4
Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2020 May 12;26(6):e50. doi: 10.1093/ibd/izaa061.
5
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.在活动性炎症性肠病中，与仅依靠临床决策相比，通过治疗药物监测来指导英夫利昔单抗剂量调整与更好的内镜检查结果相关。
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126.
6
Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.英夫利昔单抗优化治疗克服炎症性肠病患者免疫原性的长期结局。
Dig Dis Sci. 2018 Mar;63(3):761-767. doi: 10.1007/s10620-018-4917-7. Epub 2018 Jan 16.
7
Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.治疗药物监测有助于指导接受英夫利昔单抗治疗炎症性肠病的儿童的决策过程。
Acta Paediatr. 2017 Nov;106(11):1863-1867. doi: 10.1111/apa.14008. Epub 2017 Aug 24.
8
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
9
Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.利用治疗药物监测识别一名溃疡性结肠炎患者中英夫利昔单抗代谢的个体差异
J Clin Gastroenterol. 2016 Jan;50(1):66-8. doi: 10.1097/MCG.0000000000000370.
10
[Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].[英夫利昔单抗治疗监测在炎症性肠病治疗中的效用]
Rev Med Chil. 2018 Nov;146(11):1241-1251. doi: 10.4067/S0034-98872018001101241.

引用本文的文献

1
Therapeutic drug monitoring for biological medications in inflammatory bowel disease.炎症性肠病生物药物的治疗药物监测。
Saudi J Gastroenterol. 2022 Sep-Oct;28(5):322-331. doi: 10.4103/sjg.sjg_3_22.
2
A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.一项针对英夫利昔单抗治疗炎症性肠病的多学科早期积极治疗药物监测计划的3年前瞻性研究。
Br J Clin Pharmacol. 2020 Jun;86(6):1165-1175. doi: 10.1111/bcp.14229. Epub 2020 Feb 21.